|
Supplemental Materials for manuscript submitted to Gastroenterology |
|
Click here to access Supplemental Materials submitted to Gastroenterolgoy entitled "Consensus recommendations on sequence analysis and resistance monitoring in hepatitis C virus drug development".
|
|
|
HCV Drug Resistance Slide Set |
|
Recognizing the need for education
regarding HCV drug resistance, the Forum for Collaborative HIV Research's HCV
Drug Development Advisory Group (academicians, clinicians, researchers and
patient advocates) have contributed to a slide deck explaining resistance in
HCV, its consequences as well as its mitigation.
|
|
Read more...
|
|
|
HEP DART 2009, Frontiers in Drug Development for Viral Hepatitis Education Round-Table |
|
An education roundtable will be at held the upcoming HEP DART meeting in
Hawaii On Tuesday, December 8, 2009 to educate Hepatitis C virus
infected patients and update physicians who treat them about risk for,
and avoidance of drug resistance to the next generation of HCV antiviral
therapies.
|
|
Read more...
|
|
|
IV. HCV Drug Resistance Advisory Group, November 2009 |
|
The Fourth HCV Drug Resistance Advisory Group (HCV DRAG) meeting was held to discuss HCV drug resistance issues for directly acting antivirals in clinical trials.
|
|
Read more...
|
|
|
III. HCV Drug Resistance Advisory Group, March 2009 |
|
The HCV Drug Resistance Advisory Group (HCV DRAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006.
|
|
Read more...
|
|
|
II. HCV Drug Resistance Advisory Group, November 2007 |
|
The HCV Drug Resistance Advisory Group (HCV DRAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006.
|
|
Read more...
|
|
|
I. HCV Drug Resistance Advisory Group, May 2007 |
|
The HCV Drug Resistance Advisory Group (HCV DRAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006.
|
|
Read more...
|
|
|
